Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 3.41% based on its latest 2019Q2 regulatory filing with the SEC. Bvf Inc sold 50,000 shares as the company’s stock declined 38.33% . The hedge fund held 1.41 million shares of the health care company at the end of 2019Q2, valued at $13.16 million, down from 1.46M at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $442.12M market cap company. The stock decreased 1.68% or $0.13 during the last trading session, reaching $7.59. About 472,767 shares traded or 16.67% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since October 12, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M
Adirondack Trust Co increased its stake in Lockheed Martin Corp (LMT) by 22.91% based on its latest 2019Q2 regulatory filing with the SEC. Adirondack Trust Co bought 1,041 shares as the company’s stock rose 9.14% . The institutional investor held 5,584 shares of the military and government and technical company at the end of 2019Q2, valued at $2.03 million, up from 4,543 at the end of the previous reported quarter. Adirondack Trust Co who had been investing in Lockheed Martin Corp for a number of months, seems to be bullish on the $107.73 billion market cap company. The stock decreased 1.40% or $5.41 during the last trading session, reaching $381.47. About 1.22M shares traded or 12.16% up from the average. Lockheed Martin Corporation (NYSE:LMT) has risen 13.14% since October 12, 2018 and is uptrending. It has outperformed by 13.14% the S&P500. Some Historical LMT News: 24/04/2018 – LOCKHEED MARTIN CORP SEES 2018 SHR $15.80 TO $16.10; 11/04/2018 – Channel NewsAsia: Exclusive: Pentagon stops accepting Lockheed F-35 jets over repair cost dispute; 03/04/2018 – NASA awards $247.5 million cost-plus contract to Lockheed Martin to design and build a supersonic aircraft that does not create a traditional sonic boom; 03/04/2018 – LOCKHEED MARTIN WAS ONLY BIDDER ON NASA SUPERSONIC TEST PLANE; 28/03/2018 – U.S. weapons maker Raytheon eyes deal with Poland on more Patriot systems; 05/05/2018 – UNITED LAUNCH ALLIANCE ROCKET CARRYING NASA’S LATEST ROBOT MARS LANDER BLASTS OFF FROM VANDENBERG AIR FORCE BASE IN CALIFORNIA; 24/04/2018 – LOCKHEED SEES FY EPS $15.80 TO $16.10, SAW $15.20 TO $15.50; 17/04/2018 – Lockheed Martin: Lockheed Martin Provides Commonwealth of Australia with Space Situational Awareness System Apr 17, 2018; 14/04/2018 – Lockheed Martin-Led Team Hosts Christening for Future USS INDIANAPOLIS; 11/04/2018 – US News: Exclusive: Pentagon Stops Accepting F-35 Jets From Lockheed Over Repair Cost Dispute
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on November, 14. They expect $-0.27 earnings per share, down 22.73% or $0.05 from last year’s $-0.22 per share. After $-0.26 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 3.85% negative EPS growth.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Finance.Yahoo.com which released: “ChemoCentryx (CCXI) Moves to Buy: Rationale Behind the Upgrade – Yahoo Finance” on May 20, 2019, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For September 12, 2019 – Benzinga” published on September 12, 2019, Seekingalpha.com published: “ChemoCentryx 2017 Q4 – Results – Earnings Call Slides – Seeking Alpha” on March 09, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx withdraws conditional approval application for avacopan in Europe – Seeking Alpha” published on January 24, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock – GlobeNewswire” with publication date: September 27, 2018.
Bvf Inc, which manages about $999.89 million and $915.61M US Long portfolio, upped its stake in Cytomx Therapeutics Inc by 675,617 shares to 1.87M shares, valued at $21.02M in 2019Q2, according to the filing. It also increased its holding in Calithera Biosciences Inc (NASDAQ:CALA) by 3.73M shares in the quarter, for a total of 6.75M shares, and has risen its stake in Replimune Group Inc.
Investors sentiment increased to 1.89 in 2019 Q2. Its up 0.45, from 1.44 in 2019Q1. It is positive, as 9 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 46 raised stakes. 36.18 million shares or 8.54% more from 33.34 million shares in 2019Q1 were reported. Assetmark owns 54 shares. Legal & General Gp Public Ltd Com has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 8,358 shares. Farallon Capital Management Limited Liability Company reported 0.15% stake. Pub Employees Retirement System Of Ohio owns 108,799 shares. Dekabank Deutsche Girozentrale holds 0% or 33,000 shares in its portfolio. Credit Suisse Ag invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fmr Ltd Liability holds 0.01% or 5.66 million shares in its portfolio. Strs Ohio holds 59,600 shares. Wasatch Advisors holds 3.00 million shares. Renaissance Tech Ltd Limited Liability Company has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.47 million shares. Employees Retirement System Of Texas owns 35,000 shares. Ameritas Investment Prtnrs Inc accumulated 3,509 shares. Sectoral Asset Mngmt accumulated 0.02% or 17,811 shares. 14,824 are held by Raymond James And. Northern Tru Corporation owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 357,403 shares.
Since August 9, 2019, it had 1 buy, and 0 insider sales for $509,534 activity.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.